Press coverage about Adaptimmune Therapeutics (NASDAQ:ADAP) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.6956637796764 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Do Relative Strength Index Hits Key Level? – Adaptimmune Therapeutics (NASDAQ: ADAP) (financerater.com)
- Adaptimmune Therapeutics plc – Receive News & Ratings Daily (styleonfleek365.com)
- Adaptimmune Therapeutics (ADAP) Presents MAGE-A4 and MAGE-A10 pre-clinical data at AACR (streetinsider.com)
- Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting (finance.yahoo.com)
- Soft Tissue Sarcoma – Pipeline Insight, 2018 Market Report; Launched via MarketResearchReports.com (canadianbusinesstribune.com)
Shares of ADAP opened at $12.36 on Tuesday. Adaptimmune Therapeutics has a fifty-two week low of $4.28 and a fifty-two week high of $13.41.
ADAP has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 19th. BidaskClub cut shares of Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Leerink Swann initiated coverage on shares of Adaptimmune Therapeutics in a report on Friday, March 16th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $11.58.
In other news, CFO Adrian Rawcliffe sold 600,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total value of $1,026,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David M. Mott bought 869,574 shares of the company’s stock in a transaction dated Thursday, March 22nd. The stock was purchased at an average price of $1.90 per share, for a total transaction of $1,652,190.60. The disclosure for this purchase can be found here. In the last quarter, insiders bought 9,385,254 shares of company stock worth $17,966,655. Insiders own 24.45% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Adaptimmune Therapeutics (ADAP) Earning Somewhat Positive News Coverage, Report Shows” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://weekherald.com/2018/04/17/adaptimmune-therapeutics-adap-earning-somewhat-positive-news-coverage-report-shows.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.